MX2019015371A - Derivados de dihidro-pirrolo-piridina. - Google Patents
Derivados de dihidro-pirrolo-piridina.Info
- Publication number
- MX2019015371A MX2019015371A MX2019015371A MX2019015371A MX2019015371A MX 2019015371 A MX2019015371 A MX 2019015371A MX 2019015371 A MX2019015371 A MX 2019015371A MX 2019015371 A MX2019015371 A MX 2019015371A MX 2019015371 A MX2019015371 A MX 2019015371A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- pyrrolo
- dihydro
- pyridine derivatives
- compounds
- Prior art date
Links
- JKWQHCSGMTWRIQ-UHFFFAOYSA-N 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine Chemical class C1=CC=C2NCCC2=N1 JKWQHCSGMTWRIQ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 <i>N</i>-oxides Chemical class 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523306P | 2017-06-22 | 2017-06-22 | |
| PCT/IB2018/054390 WO2018234953A1 (en) | 2017-06-22 | 2018-06-14 | Dihydro-pyrrolo-pyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019015371A true MX2019015371A (es) | 2020-07-20 |
Family
ID=62981279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015371A MX2019015371A (es) | 2017-06-22 | 2018-06-14 | Derivados de dihidro-pirrolo-piridina. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11198692B2 (enExample) |
| EP (1) | EP3642202B1 (enExample) |
| JP (1) | JP7263266B2 (enExample) |
| KR (1) | KR20200013783A (enExample) |
| CN (1) | CN110944998B (enExample) |
| AU (1) | AU2018287787A1 (enExample) |
| BR (1) | BR112019026955A2 (enExample) |
| CA (1) | CA3066986A1 (enExample) |
| DK (1) | DK3642202T3 (enExample) |
| ES (1) | ES2937236T3 (enExample) |
| FI (1) | FI3642202T3 (enExample) |
| HU (1) | HUE060914T2 (enExample) |
| IL (1) | IL271290B2 (enExample) |
| MX (1) | MX2019015371A (enExample) |
| PL (1) | PL3642202T3 (enExample) |
| PT (1) | PT3642202T (enExample) |
| SG (1) | SG11201913014YA (enExample) |
| TW (1) | TWI680128B (enExample) |
| WO (1) | WO2018234953A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4061813B1 (en) * | 2019-11-22 | 2025-06-04 | F. Hoffmann-La Roche AG | Pyrrolidine derivatives |
| CN112174869B (zh) * | 2020-10-12 | 2023-04-25 | 蔡霈 | N-苯乙酰基-2-羟甲基吡咯烷-2-甲酰胺的制备方法及其药用用途 |
| JP2025534061A (ja) * | 2022-10-28 | 2025-10-09 | 紐欧申医薬（上海）有限公司 | 窒素含有複素環化合物、その薬学的に許容される塩及びその調製方法と使用 |
| KR20250121123A (ko) | 2022-12-16 | 2025-08-11 | 카루나 세러퓨틱스 인코포레이티드 | 치환된 테트라히드로피롤로-피리디논 화합물 및 의학적 병태를 치료하는 데 있어서의 이의 용도 |
| WO2024130065A1 (en) * | 2022-12-16 | 2024-06-20 | Karuna Therapeutics, Inc. | Substituted dihydropyrrolo[3, 4-d]pyrimidine compounds and their use in treating medical conditions |
| JP2025541362A (ja) * | 2022-12-16 | 2025-12-18 | カルナ セラピューティクス，インコーポレイテッド | 置換テトラヒドロピロロ－ピリジノン化合物及び医学的状態の治療におけるその使用 |
| CN120641421A (zh) * | 2022-12-16 | 2025-09-12 | 卡鲁娜治疗学有限公司 | 经取代的二氢吡咯并[3,4-d]嘧啶化合物及其在治疗医学病状中的用途 |
| KR20250130620A (ko) * | 2022-12-16 | 2025-09-02 | 카루나 세러퓨틱스 인코포레이티드 | 치환된 테트라하이드로피롤로-피리디논 화합물 및 의학적 병태 치료에서의 이의 용도 |
| WO2024260386A1 (zh) * | 2023-06-20 | 2024-12-26 | 西藏海思科制药有限公司 | 毒蕈碱m4受体激动剂及其用途 |
| WO2025055970A1 (zh) * | 2023-09-15 | 2025-03-20 | 江苏恩华药业股份有限公司 | 氮杂环丁烷衍生物、其制备方法及其医药用途 |
| WO2025083630A1 (en) | 2023-10-19 | 2025-04-24 | Suven Life Sciences Limited | Heteroaromatic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
| WO2025099660A1 (en) | 2023-11-10 | 2025-05-15 | Suven Life Sciences Limited | Piperidine substituted compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
| WO2025103475A1 (zh) * | 2023-11-17 | 2025-05-22 | 上海翰森生物医药科技有限公司 | 杂环羰基类衍生物调节剂、其制备方法和应用 |
| WO2025122809A1 (en) * | 2023-12-07 | 2025-06-12 | Acadia Pharmaceuticals Inc. | M4 positive allosteric modulators |
| WO2025131049A1 (en) * | 2023-12-21 | 2025-06-26 | Ignis Therapeutics (Suzhou) Limited | Dihydro-pyrrolo-pyridine derivatives and uses thereof |
| WO2025134078A1 (en) | 2023-12-22 | 2025-06-26 | Suven Life Sciences Limited | Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams) |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3123612A (en) | 1964-03-03 | Z-acylated z | ||
| US2767191A (en) | 1953-12-31 | 1956-10-16 | American Cyanamid Co | Dihydropyrrolo-pyridines |
| WO1994017197A1 (fr) | 1993-01-25 | 1994-08-04 | Takeda Chemical Industries, Ltd. | ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| NZ337765A (en) | 1997-04-09 | 2001-09-28 | Mindset Biopharmaceuticals Usa | Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| JP2000109481A (ja) * | 1999-10-13 | 2000-04-18 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体含有医薬 |
| SI1257584T2 (sl) | 2000-02-24 | 2013-07-31 | Washington University St. Louis | Humanizirana protitelesa, ki veĹľejo amiloidni peptid beta |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| CA2427661C (en) | 2000-11-03 | 2013-05-28 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| US20040192898A1 (en) | 2001-08-17 | 2004-09-30 | Jia Audrey Yunhua | Anti-abeta antibodies |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| BR0315157A (pt) | 2002-10-09 | 2005-08-09 | Rinat Neuroscience Corp | Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| EP1638935A1 (en) | 2003-06-19 | 2006-03-29 | Pfizer Products Inc. | Nk1 antagonist |
| CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| BRPI0507374A (pt) | 2004-02-02 | 2007-07-10 | Pfizer Prod Inc | moduladores do receptor de histamina-3 |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| MX2007004794A (es) | 2004-10-25 | 2007-07-09 | Lilly Co Eli | Tienopiridinas como potenciadores alostericos del receptor muscarinico m4. |
| US20090074775A1 (en) | 2004-12-22 | 2009-03-19 | David Michael Holtzman | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury |
| DK1848694T3 (da) * | 2005-02-07 | 2010-01-25 | Hoffmann La Roche | Heterocykliske substituerede phenylmethanoner som inhibitorer af glycintransporter |
| MY148086A (en) | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
| US8227475B2 (en) | 2005-05-12 | 2012-07-24 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
| WO2006126082A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| US7812040B2 (en) | 2005-06-22 | 2010-10-12 | Pfizer Inc. | Histamine-3 receptor antagonists |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| WO2007052124A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| WO2007105053A2 (en) | 2006-03-13 | 2007-09-20 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| HRP20110539T1 (hr) | 2006-04-21 | 2011-08-31 | Pfizer Products Inc. | PIRIDINO[3,4-b]PIRAZINONI |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| CA2676456C (en) | 2007-01-22 | 2012-03-27 | Pfizer Products Inc. | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
| US20100273772A1 (en) * | 2009-04-23 | 2010-10-28 | Wyeth Llc | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) |
| WO2012047702A1 (en) | 2010-10-04 | 2012-04-12 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators |
| AR083855A1 (es) | 2010-11-15 | 2013-03-27 | Abbott Lab | Inhibidores de nampt y rock |
| WO2013126856A1 (en) | 2012-02-23 | 2013-08-29 | Vanderbilt University | Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| WO2014035829A1 (en) * | 2012-08-31 | 2014-03-06 | Vanderbilt University | Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators |
| WO2015027214A1 (en) * | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| US20160200733A1 (en) | 2013-08-23 | 2016-07-14 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| DK3478679T3 (da) | 2016-07-01 | 2021-06-21 | Pfizer | 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
-
2018
- 2018-06-14 FI FIEP18743584.7T patent/FI3642202T3/fi active
- 2018-06-14 EP EP18743584.7A patent/EP3642202B1/en active Active
- 2018-06-14 AU AU2018287787A patent/AU2018287787A1/en not_active Abandoned
- 2018-06-14 KR KR1020207001865A patent/KR20200013783A/ko not_active Withdrawn
- 2018-06-14 CN CN201880049365.XA patent/CN110944998B/zh active Active
- 2018-06-14 ES ES18743584T patent/ES2937236T3/es active Active
- 2018-06-14 JP JP2019570547A patent/JP7263266B2/ja active Active
- 2018-06-14 US US16/625,202 patent/US11198692B2/en active Active
- 2018-06-14 CA CA3066986A patent/CA3066986A1/en active Pending
- 2018-06-14 PL PL18743584.7T patent/PL3642202T3/pl unknown
- 2018-06-14 SG SG11201913014YA patent/SG11201913014YA/en unknown
- 2018-06-14 HU HUE18743584A patent/HUE060914T2/hu unknown
- 2018-06-14 PT PT187435847T patent/PT3642202T/pt unknown
- 2018-06-14 MX MX2019015371A patent/MX2019015371A/es unknown
- 2018-06-14 IL IL271290A patent/IL271290B2/en unknown
- 2018-06-14 BR BR112019026955-0A patent/BR112019026955A2/pt not_active Application Discontinuation
- 2018-06-14 DK DK18743584.7T patent/DK3642202T3/da active
- 2018-06-14 WO PCT/IB2018/054390 patent/WO2018234953A1/en not_active Ceased
- 2018-06-19 TW TW107120944A patent/TWI680128B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200262833A1 (en) | 2020-08-20 |
| CA3066986A1 (en) | 2018-12-27 |
| WO2018234953A1 (en) | 2018-12-27 |
| NZ760036A (en) | 2025-05-30 |
| AU2018287787A1 (en) | 2020-01-16 |
| FI3642202T3 (fi) | 2023-03-01 |
| IL271290B1 (en) | 2023-07-01 |
| ES2937236T3 (es) | 2023-03-27 |
| DK3642202T3 (da) | 2023-01-30 |
| HUE060914T2 (hu) | 2023-04-28 |
| CN110944998A (zh) | 2020-03-31 |
| PL3642202T3 (pl) | 2023-03-13 |
| JP2020524687A (ja) | 2020-08-20 |
| TWI680128B (zh) | 2019-12-21 |
| IL271290A (en) | 2020-01-30 |
| KR20200013783A (ko) | 2020-02-07 |
| US11198692B2 (en) | 2021-12-14 |
| SG11201913014YA (en) | 2020-01-30 |
| BR112019026955A2 (pt) | 2020-06-30 |
| CN110944998B (zh) | 2022-08-16 |
| IL271290B2 (en) | 2023-11-01 |
| EP3642202A1 (en) | 2020-04-29 |
| JP7263266B2 (ja) | 2023-04-24 |
| TW201920166A (zh) | 2019-06-01 |
| EP3642202B1 (en) | 2022-11-02 |
| PT3642202T (pt) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
| MX386258B (es) | Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas | |
| MX2022005399A (es) | Compuestos. | |
| MX2020013099A (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina. | |
| PH12018500087A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| MY208632A (en) | Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors | |
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX2019008690A (es) | Compuestos espiro heterociclicos como inhibidores de magl. | |
| MX2022016276A (es) | Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. | |
| MX2022010520A (es) | Macrociclos peptidicos contra acinetobacter baumannii. | |
| MX390302B (es) | Oxiesteroles y metodos de uso de los mismos | |
| MX2019008626A (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). | |
| TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| MX2020010690A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| EA200901373A1 (ru) | Аминогетероциклические соединения | |
| JOP20190233A1 (ar) | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون | |
| TN2019000204A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| PH12016501863A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| SG10201806809QA (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| MY193754A (en) | Treatment for parkinson's disease | |
| PH12016501993A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| MX2020007985A (es) | Inhibicion del canal ionico receptor de potencial transitorio a1. | |
| PH12019501566B1 (en) | Amide compounds and use thereof | |
| TN2017000448A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease |